Dose individualisation in patients with renal insufficiency: Does drug labelling support optimal management?

European Journal of Clinical Pharmacology

Volumn 60, Issue 11, 2005, Pages 807-811

  Martin Facklam, Meret ^a   Rengelshausen, Jens ^a   Tayrouz, Yorki ^a   Ketabi Kiyanvash, Nahal ^a   Lindenmaier, Heike ^a   Schneider, Verena ^a   Bergk, Verena ^a   Haefeli, Walter E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Dose individualisation; Drug labelling; Renal insufficiency

Indexed keywords

ACICLOVIR; ALIZAPRIDE; ALLOPURINOL; AMISULPRIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BISOPROLOL; BLOOD DERIVATIVE; CEFOTAXIME; CILASTATIN PLUS IMIPENEM; CLONIDINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELECTROLYTE; GABAPENTIN; HERBACEOUS AGENT; IMMUNOGLOBULIN; LEVOFLOXACIN; LITHIUM CHLORIDE; METFORMIN; PIPERACILLIN PLUS TAZOBACTAM; RANITIDINE; TAZOBACTAM; VANCO; VANCOMYCIN; VENLAFAXINE;

ARTICLE; COMPARATIVE STUDY; CREATININE CLEARANCE; DOSE CALCULATION; DRUG ACCUMULATION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG INFORMATION; DRUG LABELING; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MEDICAL INFORMATION; MEDICAL RECORD; NEPHROTOXICITY; PRIORITY JOURNAL; UNIVERSITY HOSPITAL;

CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG LABELING; GERMANY; HUMANS; KIDNEY FAILURE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 15444371753     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0852-y     Document Type: Article

References (22)

1. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R, Vander Vliet M, Nemeskal R, Leape LL (1995) Incidence of adverse drug events and potential adverse drug events. JAMA 274:29-34
2. Bergk V, Gasse C, Schnell R, Haefeli WE (2004) Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. Eur J Clin Pharmacol 60:595-602
3. Connelly DP, Rich EC, Curley SP, Kelly JT (1990) Knowledge resource preferences of family physicians. J Fam Pract 30:353-359
4. Dettli L (1984) The kidney in pre-clinical and clinical pharmacokinetics. Jpn J Clin Pharmacol Ther 15:241-254
5. Dettli L (1996) Pharmakokinetische Daten für die Dosisanpassung. In: Grundlagen der Arzneimitteltherapie. Herausgegeben durch die Sektion Klinische Pharmakologie der Schweizerischen Gesellschaft für Pharmakologie und Toxikologie. 14. Auflage. Basel: Documed, pp 13-21
6. Dollery C (ed) (1999) Therapeutic drugs, 2nd edn. Churchill Livingstone, Edinburgh
7. European Commission (1999) A guideline on the summary of product characteristics. Final - revision 0. Available at: http:// pharmacos.eudra.org/ F2/eudralex/vol-2/C/SPCGuidRev0Dec99.pdf. Accessed December 7, 2004
8. FachInfo-Service, Fachinformationsverzeichnis Deutschland. BPI Service GmbH, http://www.fachinfo.de/. Accessed between 27 Feb 2003 and 30 Jan 2004
9. Falconnier AD, Haefeli WE, Schoenenberger RA, Surber C, Martin-Facklam M (2001) Drug dosage in patients with renal failure optimized by immediate concurrent feedback. J Gen Intern Med 16:369-375
10. Jick H (1977) Adverse drug effects in relation to renal function. Am J Med 62:514-517
11. Klasco RK (ed) DRUGDEX System. MICROMEDEX Inc. Greenwood Village, Colorado, versions used: first quarter 2003 - first quarter 2004
12. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 279:1200-1205
13. Marroum PJ, Gobburu J (2002) The product label: how pharmacokinetics and pharmacodynamics reach the prescriber. Clin Pharmacokinet 41:161-169
14. Medscape Druglnfo. http://www.medscape.com/druginfo. Accessed on 5 September 2003 and 21 April 2004
15. Mullen WH, Anderson IB, Kim SY, Blanc PD, Olson KR (1997) Incorrect overdose management advice in the Physicians' Desk Reference. Ann Emerg Med 29:255-61
16. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney disease outcome quality initiative. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. Am J Kidney Dis 39:S76-S110
17. Pestotnik SL, Classen DC, Evans RS, Stevens LE, Burke JP (1993) Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system. Ann Pharmacother 27:497-501
18. Rajpal A, Reidenberg MM (2003) Drug labeling should be kept current. Clin Pharmacol Ther 73:4-6
19. Sortis, Prescribing Information of January 2003. In: FachInfo-Service, Fachinformationsverzeichnis Deutschland. BPI Service GmbH. http://www.fachinfo. de/. Accessed on 3 Nov 2003
20. Spyker DA, Harvey ED, Harvey BE, Harvey AM, Rumack BH, Peck CC, Atkinson AJ Jr, Woosley RL, Abernethy DR, Cantilena LR (2000) Assessment and reporting of clinical pharmacology information in drug labeling. Clin Pharmacol Ther 67:196-200
21. Taeschner W, Vozeh S (1997) Pharmacokinetic drug data. In: Speight TM, Holford NHG (eds) Averyás drug treatment, 4th ed. adis International Appendix A, pp 1629-1664
22. Vioxx, Prescribing Information of August 2003. In: FachInfo-Service, Fachinformationsverzeichnis Deutschland. BPI Service GmbH. http://www.fachinfo. de/. Accessed 13 Nov 2003